Docetaxel as second-line treatment in 23 patients with advanced non-small cell lung cancer
- VernacularTitle:多西他赛二线治疗23例晚期非小细胞肺癌
- Author:
Yanming DENG
;
Guangyu WEI
;
Yaodong LIN
- Publication Type:Journal Article
- Keywords:
docetaxel;
second-line;
chemotherapy;
advanced;
non-small cell lung cancer
- From:
China Oncology
2001;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To evaluate the effectiveness and safety of the second-line treatment in patients with advanced non small cell lung cancer(NSCLC). Methods:23 patients with histologically and /or cytologically confirmed advanced NSCLC were treated with docetaxel(taxotere) 75mg/m 2 on d1 every 3 weeks. All patients had received prior platinum-containing chemotherapy and relapsed or progressed after receiving one prior chemothergpy regimen. Results:23 patients were available for evaluation: partial response (PR) was 17% (4/23), stable disease(SD)and progressive disease(PD) was 57% (13/23) and 26% (6/23), respectively, there was no complete response (CR). The response rate was 17% (4/23) and the median survival of all patients was 9 months .one -year survival rate was 39% (9/23) . Hematologic toxicity was the main side effect, and they were well tolerated. Conclusions:Taxotere as second-line treatment of NSCLC is effective, and toxicity is tolerated.
